Does State Medicaid Cover Mounjaro?

Mounjaro Medicaid Coverage: The Big Picture

Medicaid is administered at the state level, which means there is no single national Mounjaro coverage policy. For type 2 diabetes, coverage is near-universal. Every state Medicaid program includes at least some GLP-1 receptor agonists on its preferred drug list (PDL), and tirzepatide has secured formulary placement in the majority of states since its FDA approval in May 2022. The picture for weight loss is far less favorable.

Fewer than half of state Medicaid programs cover GLP-1 receptor agonists for obesity as of early 2026. Many states explicitly exclude anti-obesity medications from Medicaid benefits, a carveout that dates back decades. The Treat and Reduce Obesity Act, reintroduced in Congress multiple times, has not yet passed at the federal level, leaving each state to decide independently whether to cover weight-management drugs. Even in states that do cover anti-obesity pharmacotherapy, tirzepatide for obesity is branded as Zepbound, not Mounjaro, and may carry separate formulary rules.

A 2023 analysis published in Obesity found that only 15 state Medicaid programs covered at least one anti-obesity medication without severe restrictions, while the rest either excluded them outright or imposed limits so restrictive that real-world access was minimal.

How Formulary Placement Works in State Medicaid

Each state maintains a preferred drug list that determines which medications receive favorable coverage. Mounjaro sits on these PDLs in one of several tiers, and its placement directly affects your out-of-pocket cost and the hoops your prescriber must clear.

In states where tirzepatide is a preferred agent for type 2 diabetes, prior authorization may be streamlined or even waived. In states where it is non-preferred, your prescriber will need to document clinical justification, often proving that cheaper alternatives failed first. The SURPASS-2 trial (N=1,879) demonstrated that tirzepatide 15 mg reduced HbA1c by 2.58% compared with 1.86% for semaglutide 1 mg at 40 weeks, data your prescriber can cite in a prior authorization request to argue for tirzepatide over a preferred GLP-1.

States update their PDLs on a quarterly or semiannual cycle. A drug that is non-preferred today may become preferred after the next Pharmacy and Therapeutics Committee review. Your state Medicaid pharmacy helpline can confirm current formulary status.

Formulary tier designations across state Medicaid programs typically fall into these categories:

• Preferred, no PA: Covered with standard copay (usually $0 to $3 for Medicaid). Rare for Mounjaro.
• Preferred, PA required: Covered at favorable copay once prior authorization criteria are met. This is the most common placement for tirzepatide in T2D.
• Non-preferred, PA required: Covered only after documenting failure of preferred agents. Higher administrative burden.
• Not listed / excluded: Not on the formulary at all for a given indication. Common for the obesity indication in states that exclude anti-obesity drugs.

Prior Authorization Requirements for Mounjaro on Medicaid

Prior authorization is the gate most Medicaid beneficiaries must pass through. The specifics vary by state, but common criteria include a confirmed diagnosis of type 2 diabetes (ICD-10 code E11.x), a recent HbA1c value (typically 7.0% or above), documentation that metformin was tried and either failed or is contraindicated, and prescriber attestation that the patient is not using the drug solely for weight loss.

Some states go further. Texas Medicaid, for example, requires failure of two preferred agents before approving a non-preferred GLP-1. New York Medicaid requires a clinical peer-to-peer review if the initial PA is denied. California's Medi-Cal program updated its GLP-1 criteria in 2024 to include tirzepatide as a preferred option for T2D after step therapy with metformin, reducing administrative burden for prescribers in that state.

PA approvals are time-limited. Most states authorize Mounjaro for 6 to 12 months before requiring renewal. At renewal, you will typically need an updated HbA1c showing clinical response (commonly defined as a reduction of at least 0.5% from baseline or maintenance below a target threshold).

The American Diabetes Association Standards of Care (2025) recommend GLP-1 or dual GIP/GLP-1 receptor agonists as second-line therapy after metformin for patients with established cardiovascular disease, heart failure, or chronic kidney disease, guidance your prescriber can reference in the PA submission.

Step Therapy: What You Will Need to Try First

Step therapy is a cost-control mechanism that requires patients to try (and fail) less expensive drugs before a payer will approve a more costly one. For Mounjaro on Medicaid, step therapy is the norm rather than the exception.

The most common step therapy sequence looks like this:

1. Metformin (first-line, per ADA guidelines). Nearly every state requires a trial of metformin unless the patient has a documented contraindication such as an eGFR below 30 mL/min/1.73m² or a history of lactic acidosis.
2. A sulfonylurea or preferred GLP-1 agonist (second step). States with aggressive cost controls may require trial and failure of a preferred GLP-1 such as dulaglutide (Trulicity) or liraglutide before approving tirzepatide.
3. Tirzepatide (third step, if non-preferred). Approved only after documentation that prior agents did not achieve glycemic targets or caused intolerable side effects.

"Failure" typically means one of three things: the patient did not reach their HbA1c goal after 90 days at a therapeutic dose, the patient experienced a serious or intolerable adverse effect, or the patient has a medical contraindication. Documentation must be specific. A note in the chart that says "metformin did not work" is usually insufficient. States want dates, doses, duration, and outcomes.

In the SURPASS-2 trial, 86% to 92% of tirzepatide-treated participants reached an HbA1c below 7.0%, compared with 79% of those on semaglutide 1 mg [1]. This superiority data supports PA requests, particularly for patients who have not reached target on semaglutide or another GLP-1.

State-by-State Coverage Snapshots

Medicaid rules change frequently, and the details below reflect the most recent publicly available PDLs as of early 2026. Always verify with your state Medicaid pharmacy program before assuming coverage.

States with tirzepatide as a preferred T2D agent (PA still required in most): California, New York, Illinois, Ohio, Pennsylvania, Michigan, and New Jersey have added tirzepatide to their preferred lists for type 2 diabetes, though specific PA criteria differ.

States with tirzepatide as non-preferred for T2D: Texas, Florida, Georgia, and North Carolina list tirzepatide as non-preferred, meaning step therapy through at least one preferred GLP-1 is required before approval.

States covering GLP-1s for obesity: A small but growing number of states, including New York, California, Connecticut, Minnesota, and a handful of others, have begun covering anti-obesity medications under Medicaid. Even in these states, the covered product for weight loss is Zepbound (tirzepatide for obesity), not Mounjaro, and separate PA criteria apply.

States explicitly excluding anti-obesity drugs: The majority of state Medicaid programs still exclude anti-obesity medications from coverage entirely. A Kaiser Family Foundation survey found that 28 states had explicit statutory or regulatory exclusions for weight-loss drugs in their Medicaid programs as of 2024.

The passage of state-level legislation can change this rapidly. Several states introduced bills in their 2025 and 2026 legislative sessions to mandate Medicaid coverage of anti-obesity pharmacotherapy, driven by data showing that GLP-1 treatment reduces downstream costs from cardiovascular events, joint replacements, and diabetes complications.

How to Appeal a Medicaid Denial of Mounjaro

A denial is not the end of the road. Every state Medicaid program is required by federal law (42 CFR § 431.200) to provide a fair hearing process when a claim or prior authorization is denied. The appeal process generally follows these steps:

Step 1: Request the denial letter. The letter must state the specific reason for denial and cite the clinical criteria that were not met. If you did not receive a letter, contact your Medicaid managed care plan or the state fee-for-service pharmacy program.

Step 2: File a plan-level appeal. If your Medicaid benefits are administered through a managed care organization (MCO), you must first exhaust the MCO's internal appeal process. This typically involves your prescriber submitting additional clinical documentation, such as lab results, prior medication history, or a letter of medical necessity.

Step 3: Request a state fair hearing. If the MCO upholds its denial, you have the right to a state fair hearing. Deadlines vary (typically 30 to 120 days from the denial notice), and hearings may be conducted by phone or in person. You can represent yourself or bring an advocate.

Step 4: Gather supporting evidence. Strong appeals include the prescriber's letter of medical necessity, lab results showing inadequate glycemic control on prior agents, documentation of adverse effects from step-therapy drugs, and citations to clinical guidelines. The ADA Standards of Care and SURPASS trial data are particularly useful. In SURPASS-2, tirzepatide 15 mg produced a 12.4 kg mean weight reduction alongside its glycemic benefits, a dual-outcome argument that can strengthen an appeal for patients with both T2D and obesity [1].

Step 5: Expedited review. If your prescriber believes a standard appeal timeline poses a serious risk to your health, they can request an expedited review, which most states must process within 72 hours.

Success rates for Medicaid fair hearings vary by state. Anecdotal data from patient advocacy organizations suggests that appeals with strong prescriber documentation and guideline citations overturn initial denials roughly 40% to 60% of the time, though no national database tracks this systematically.

Manufacturer Savings Cards and Medicaid

Eli Lilly offers a savings card program for commercially insured patients that can reduce Mounjaro's out-of-pocket cost to as little as $25 per month. Medicaid beneficiaries cannot use this card. Federal anti-kickback statutes (42 U.S.C. § 1320a-7b) prohibit manufacturers from offering copay assistance to patients enrolled in federal healthcare programs, including Medicaid, Medicare, and TRICARE.

If you are on Medicaid and facing high costs (rare, since Medicaid copays are typically capped at $0 to $8 for brand-name drugs), your options include:

• Eli Lilly's Patient Assistance Program (Lilly Cares): For patients who are uninsured or underinsured. Medicaid enrollees are generally not eligible, but if you lose Medicaid coverage during a redetermination cycle, you may qualify temporarily.
• 340B pharmacy pricing: Certain safety-net providers (federally qualified health centers, disproportionate-share hospitals) purchase drugs at steep discounts under the 340B program. If your prescriber is affiliated with a 340B-covered entity, the lower acquisition cost may support coverage even when the drug is non-preferred.
• State pharmaceutical assistance programs (SPAPs): A few states operate supplemental drug programs that may help cover gaps in Medicaid formularies.

Mounjaro vs. Other GLP-1s on Medicaid Formularies

Cost drives formulary decisions, and tirzepatide's $1,023 per month list price puts it at a disadvantage against older GLP-1 receptor agonists with lower net costs to Medicaid programs.

Dulaglutide (Trulicity) has been available since 2014 and carries a lower list price. Semaglutide (Ozempic) is the most widely prescribed GLP-1 but also carries a high list price (approximately $935 per month). State Medicaid programs negotiate supplemental rebates with manufacturers through the Medicaid Drug Rebate Program (MDRP), and the size of these rebates, which are confidential, determines which drug lands in the preferred slot.

A 2024 study in Diabetes Care found that Medicaid spending on GLP-1 receptor agonists increased by 340% between 2018 and 2023, from $1.2 billion to $5.3 billion annually. This spending pressure is a primary reason states impose strict PA and step therapy requirements on newer, more expensive agents like tirzepatide.

From a clinical standpoint, tirzepatide's dual GIP/GLP-1 mechanism offers advantages. The SURPASS program demonstrated HbA1c reductions of 2.01% to 2.58% across tirzepatide doses (5, 10, and 15 mg), which exceeded the efficacy of semaglutide 1 mg in head-to-head comparison [1]. For patients who have not reached their glycemic target on semaglutide or dulaglutide, this data provides a clinical rationale for tirzepatide that prescribers can use in PA and appeal submissions.

What to Do If Your State Does Not Cover Mounjaro

If tirzepatide is not on your state's Medicaid formulary or is denied after appeal, several alternative paths exist.

Prescribers can submit an exception request (sometimes called a non-formulary exception or medical necessity override) outside the standard PA process. These requests go directly to the state's Medicaid medical director and require strong clinical justification.

If you have both Medicaid and a qualifying condition like type 2 diabetes with cardiovascular risk, your prescriber may be able to argue that tirzepatide is medically necessary under the Early and Periodic Screening, Diagnostic and Treatment (EPSDT) benefit, which applies to Medicaid beneficiaries under age 21 and requires states to cover any FDA-approved drug that is medically necessary regardless of formulary status.

Patients can also contact Eli Lilly's Mounjaro support line (1-833-807-6678) for assistance navigating coverage barriers. Lilly employs reimbursement specialists who can help prescribers complete PA paperwork and identify state-specific pathways.

For patients with T2D whose primary goal is glycemic control, switching to a preferred GLP-1 agonist on the state's PDL may be the most practical short-term option, with a plan to re-request tirzepatide at the next formulary review cycle if the preferred agent does not achieve adequate control.